Bank of New York Mellon’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Bank of New York Mellon’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,080	Closed	-$18.2K	–	4447
2023 Q2	$18.2K	Sell	10,080 -74,246	-88%	-$136K	﹤0.01%	4297
2023 Q1	$111K	Hold	84,326	–	–	﹤0.01%	4056
2022 Q4	$143K	Buy	84,326 +4,833	+6%	+$6.12K	﹤0.01%	4067
2022 Q3	$147K	Buy	79,493 +15,203	+24%	+$45.3K	﹤0.01%	4121
2022 Q2	$197K	Buy	64,290 +53,953	+522%	+$329K	﹤0.01%	4063
2022 Q1	$75K	Buy	+10,337	New	+$102K	﹤0.01%	4460

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Bank of New York Mellon's PRDS Position: Q3 2023 in Review

Bank of New York Mellon sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 10,080 shares — an estimated $18.2K sold.

Bank of New York Mellon first reported a position in PRDS in Q1 2022 and held it in 6 quarters. The position peaked at $197K in Q2 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Bank of New York Mellon reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Bank of New York Mellon sold 10,080 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $18.2K.
Bank of New York Mellon first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Bank of New York Mellon's Pardes Biosciences, Inc. Common Stock position peaked at $197K in Q2 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Bank of New York Mellon's 13F filing for Q3 2023, filed 24 Oct 2023.